This is a product review of the use of Symtuza in the treatment of Human Immunodeficiency Virus-1 infection. This review discusses the evidence in support of the use of Symtuza, its dosage, interactions, safety, and efficacy and tolerability demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Andrew Carr, Director of the HIV, Immunology and Infectious Diseases Unit, and Head of the Clinical Research Program, Centre for Applied Medical Research at St Vincent’s Hospital Sydney, and Professor of Medicine, UNSW.
Please login below to download this issue (PDF)